Enter your keywords
Overview The NHS Long Term Plan outlines that 4% of the total NHS carbon footprint savings are expected to be realised through a ‘shift to lower carbon inhalers’ equivalent to a 50% reduction in the inhaler carbon footprint. 1,2 The RDTC has developed an inhaler carbon impact assessment tool in response to these targets. It […]
Overview The charts included within this report are organised by BNF classification (legacy) and show comparative costs at the NHS basic price1,2 (as of January 2024) for selected agents. Except where indicated otherwise, each chart shows the cost of 1 year3 of treatment at a commonly prescribed daily dose (shown in brackets). The doses given […]
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]
This poster was presented at the Clinical Pharmacy Congress North, November 2023 in Manchester. It was previously presented at the Great North Pharmacy Research Collaborative in July 2023. It investigates the impact of social prescribing on primary care prescribing of medicines in practices with a high level of deprivation; find the poster and abstract below. Download the poster […]
The NHS Long-Term Plan sets out a commitment to reduce NHS carbon emissions by 51% by 2025, and ultimately to become the world’s first Net-Zero health service. Good-quality data comparing the environmental impact of different types of inhalers is essential if patients and prescribers are to make informed decisions about their choice of inhalers in […]
This poster was first presented at the Great North Pharmacy Research Collaborative in July 2023. It investigates the impact of social prescribing on primary care prescribing of medicines in practices with a high level of deprivation; find the poster and abstract below. Download the poster here.
This poster was first presented at the Great North Pharmacy Research Collaborative in July 2023. It tests a simple model to estimate the carbon footprint and cost impact of reducing opioid overprescribing in the most deprived deciles; find the poster and abstract below. Download the poster here.
The full methodology is available as a preprint at medrxiv (external link). This methodology was then used to develop the RDTC’s Inhaler Carbon Footprint tool. Abstract The impact of climate change on health is increasing, as global warming continues to rise. Within the health and social care sector, pressurised metered dose inhalers (pMDIs) and breath-actuated […]
Inhalers account for approximately 3% of all NHS carbon emissions. Reducing the carbon impact from inhaler prescribing has been identified as a significant area of focus for delivering a net zero NHS. This document aims to outline strategies that can be considered to promote optimal respiratory care, while minimising the environmental impact from inhalers and […]
In recent years, there has been increasing concern regarding the overprescribing of opioids and associated harms. The RDTC has produced a series of publications as part of the Polypharmacy and Overprescribing theme reviewing opioid prescribing: Each publication includes considerations and interventions for medicines optimisation teams and health systems. To avoid duplication across this series of […]